EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
[Brackets] indicate matter deleted from existing law.
*hb0571*
HOUSE BILL 571
J1 3lr1931
CF 3lr2929
By: Delegate Kipke
Introduced and read first time: February 3, 2023
Assigned to: Health and Government Operations
A BILL ENTITLED
AN ACT concerning 1
Overdose Response Program – Opioid Overdose Reversal Drugs – Choice of 2
Formulation and Dosage 3
FOR the purpose of requiring the Maryland Department of Health to allow certain entities 4
provided opioid overdose reversal drugs by the Department under the Overdose 5
Response Program to choose the formulation or dosage of opioid overdose reversal 6
drugs approved by the federal Food and Drug Administration with which the entity 7
is to be provided; and generally relating to the Overdose Response Program. 8
BY repealing and reenacting, with amendments, 9
Article – Health – General 10
Section 13–3103 11
Annotated Code of Maryland 12
(2019 Replacement Volume and 2022 Supplement) 13
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 14
That the Laws of Maryland read as follows: 15
Article – Health – General 16
13–3103. 17
(a) The Department shall adopt regulations necessary for the administration of 18
the Program. 19
(b) The Department may: 20
(1) Collect fees necessary for the administration of the Program; 21
(2) Authorize private or public entities to conduct education and training 22
on opioid overdose recognition and response that include: 23 2 HOUSE BILL 571
(i) Education on recognizing the signs and symptoms of an opioid 1
overdose; 2
(ii) Training on responding to an opioid overdose, including the 3
administration of opioid overdose reversal drugs approved by the federal Food and Drug 4
Administration; and 5
(iii) Access to opioid overdose reversal drugs approved by the federal 6
Food and Drug Administration and the necessary supplies for the administration of the 7
opioid overdose reversal drugs; 8
(3) Develop guidance regarding the content of educational training 9
programs conducted by private or public entities; and 10
(4) Collect and report data on the operation and results of the programs. 11
(c) An individual is not required to obtain training and education on opioid 12
overdose recognition and response from a private or public entity under subsection (b) of 13
this section in order for a pharmacist to dispense an opioid overdose reversal drug approved 14
by the federal Food and Drug Administration to the individual. 15
(d) (1) Subject to the limitations of the State budget, the Department shall 16
purchase and provide opioid overdose reversal drugs approved by the federal Food and 17
Drug Administration, at no cost, to the providers who are required to offer opioid overdose 18
reversal drugs approved by the federal Food and Drug Administration under § 8–408 or § 19
19–310.3 of this article. 20
(2) An entity required to offer an opioid overdose reversal drug approved 21
by the federal Food and Drug Administration under § 8–408 or § 19–310.3 of this article 22
may provide an opioid overdose reversal drug approved by the federal Food and Drug 23
Administration only if the opioid overdose reversal drug approved by the federal Food and 24
Drug Administration is provided by the Department. 25
(3) THE DEPARTMENT SHALL ALLO W AN ENTITY THAT IS PROVIDED 26
WITH OPIOID OVERDOSE REVE RSAL DRUGS BY THE DEPARTMENT UNDER THIS 27
SUBSECTION TO CHOOSE THE FORMULATION OR DOSAGE O F OPIOID OVERDOSE 28
REVERSAL DRUG S APPROVED BY THE FEDE RAL FOOD AND DRUG ADMINISTRATION 29
WITH WHICH THE ENTIT Y IS TO BE PROVIDED . 30
SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 31
October 1, 2023. 32